Table 2.
Variable | Protocol | Assessment | n a | Mean | SD | CV | GM | Within-protocol P-valueb | Between-protocol P-valuec |
---|---|---|---|---|---|---|---|---|---|
Insulin | EU | Pre | 7 | 6.06 | 4.37 | 0.72 | 4.70 | 0.439 | 0.316 |
Post | 7 | 8.55 | 5.91 | 0.69 | 6.79 | ||||
AH | Pre | 6 | 14.24 | 14.04 | 0.98 | 7.16 | 0.510 | ||
Post | 6 | 11.48 | 7.29 | 0.64 | 10.04 | ||||
ICAM-1 | EU | Pre | 13 | 234.88 | 59.53 | 0.25 | 228.44 | 0.766 | 0.173 |
Post | 13 | 232.06 | 49.59 | 0.21 | 227.32 | ||||
AH | Pre | 10 | 222.36 | 43.50 | 0.20 | 218.48 | 0.192 | ||
Post | 10 | 217.04 | 42.98 | 0.20 | 213.08 |
Six subjects in the euglycaemia protocol and4 subjects in the acute hyperglycaemia protocol had plasma insulin levels below the limits of detection.
Within-protocol P-values reflect the point estimate for the mean pre- to post-intervention change in plasma insulin after conversion to the geometric mean ratio scale.
Between-protocol P-values represent the baseline-corrected ratio of geometric means (RGM) between protocols (i.e. RGM acute hyperglycaemia: RGM euglycaemia). AH, acute hyperglycaemia; CV, coefficient of variation; EU, euglycaemia; GM, geometric mean; ICAM-1, intercellular adhesion molecule-1.